101.49
-1.26 (-1.23%)
| Previous Close | 102.75 |
| Open | 102.75 |
| Volume | 792,139 |
| Avg. Volume (3M) | 1,942,007 |
| Market Cap | 15,792,674,816 |
| Price / Earnings (TTM) | 12.85 |
| Price / Earnings (Forward) | 24.39 |
| Price / Sales | 4.48 |
| Price / Book | 7.83 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -22.27% |
| Operating Margin (TTM) | 17.67% |
| Diluted EPS (TTM) | -6.08 |
| Quarterly Revenue Growth (YOY) | -3.30% |
| Total Debt/Equity (MRQ) | 110.09% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | 1.00 B |
| Levered Free Cash Flow (TTM) | 381.00 M |
| Return on Assets (TTM) | 4.96% |
| Return on Equity (TTM) | -23.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Illumina, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.90 |
|
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.19% |
| % Held by Institutions | 101.16% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 142.00 (Evercore ISI Group, 39.92%) | Buy |
| Median | 113.50 (11.83%) | |
| Low | 100.00 (Barclays, -1.47%) | Sell |
| Average | 115.67 (13.97%) | |
| Total | 1 Buy, 4 Hold, 1 Sell | |
| Avg. Price @ Call | 123.54 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 31 Oct 2025 | 100.00 (-1.47%) | Sell | 123.54 |
| 02 Oct 2025 | 95.00 (-6.39%) | Sell | 99.30 | |
| Canaccord Genuity | 31 Oct 2025 | 112.00 (10.36%) | Hold | 123.54 |
| Evercore ISI Group | 31 Oct 2025 | 142.00 (39.92%) | Buy | 123.54 |
| 07 Oct 2025 | 132.00 (30.06%) | Buy | 96.68 | |
| JP Morgan | 31 Oct 2025 | 105.00 (3.46%) | Hold | 123.54 |
| TD Cowen | 31 Oct 2025 | 115.00 (13.31%) | Hold | 123.54 |
| UBS | 31 Oct 2025 | 120.00 (18.24%) | Hold | 123.54 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARNARD STEVEN | - | 122.44 | -515 | -63,057 |
| DAVIES SCOTT M | - | 122.44 | -398 | -48,731 |
| ERICKSEN SCOTT D | - | 122.44 | -206 | -25,223 |
| GOTTLIEB SCOTT | 119.99 | - | 500 | 59,995 |
| LECKMAN PATRICIA | - | 122.44 | -296 | -36,242 |
| PEGELS KEVIN CARL | - | 122.44 | -599 | -73,342 |
| Aggregate Net Quantity | -1,514 | |||
| Aggregate Net Value ($) | -186,599 | |||
| Aggregate Avg. Buy ($) | 119.99 | |||
| Aggregate Avg. Sell ($) | 122.44 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BARNARD STEVEN | Officer | 05 Nov 2025 | Disposed (-) | 515 | 122.44 | 63,057 |
| PEGELS KEVIN CARL | Officer | 05 Nov 2025 | Disposed (-) | 599 | 122.44 | 73,342 |
| LECKMAN PATRICIA | Officer | 05 Nov 2025 | Disposed (-) | 296 | 122.44 | 36,242 |
| ERICKSEN SCOTT D | Officer | 05 Nov 2025 | Disposed (-) | 206 | 122.44 | 25,223 |
| DAVIES SCOTT M | Officer | 05 Nov 2025 | Disposed (-) | 398 | 122.44 | 48,731 |
| GOTTLIEB SCOTT | Director | 03 Nov 2025 | Buy (+) | 500 | 119.99 | 59,995 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |